Phospho-AKT1(Ser473) Antibody (YA227)
(Synonyms: AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_HUMAN antibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-Akt antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody; )Based on 4 publication(s) in Google Scholar
Phospho-AKT1(Ser473) Antibody (YA227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1(Ser473).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, IHC-P
-
Reactivity :
Human, Mouse, Rat, Dog
-
Formulation:
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Publications Citing Use of MedChemExpress (MCE) Phospho-AKT1(Ser473) Antibody (YA227)
More-
WB
-
WB
-
WB
-
WB
-
WB
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
IF-Tissue
IF-Tissue: Immunofluorescence-Tissue
|
IHC-F
IHC-F: Immunohistochemistry-Frozen
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:5000-1:10000 | 1:100-1:1000 | 1:200-1:1000 | 1:200-1:500 | 1:100 |
Product Details
Phospho-AKT1(Ser473) Antibody (YA227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1(Ser473).
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse, Rat, Dog
-
Observed Molecular WeightObserved band size: 56 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 56 kDa
Entrez Gene: 207 Human ; 11651 Mouse ; 24185 Rat
SwissProt: P31749 Human ; P31750 Mouse ; P47196 Rat
OMIM: 114480 Human
Synthetic phosphopeptide corresponding to residues surrounding Ser473 of Human Akt1.The exact sequence is proprietary to MCE.
Endogenous
Protein A affinity purified.
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Tougu Xiaotong capsules inhibit lung cancer and gefitinib-resistant cells by blocking ERBB2/PI3K-AKT-mTOR signaling and triggering ferroptosis. [Abstract]2026 Jan:150:157741. PMID: 41477979
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157741. [Abstract]
A549 and LLC cells were treated with increasing doses of TXC for 24 h, followed by western blotting for ERBB2, PI3K, phospho-PI3K, AKT, phospho-AKT, mTOR, phospho-Mtor.
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157741. [Abstract]
Subcutaneous LLC xenografts were established in C57BL/6 mice, the tumors were harvested on day 18. Western blot analysis of ERBB2, PI3K, phospho-PI3K, AKT, phospho-AKT, mTOR, and phospho-mTOR in tumor lysates.
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157741. [Abstract]
Western blot analysis of ERBB2, PI3K, phospho-PI3K, AKT, phospho-AKT, mTOR, phospho-mTOR, HMOX1, and GPX4 in HCC827 and HCC827-GR cells treated with TXC or gefitinib.
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157741. [Abstract]
Following 12 h of cotreatment, Western blotting for ERBB2, PI3K, phospho-PI3K, AKT, phospho-AKT, mTOR, phospho-mTOR, HMOX1, GPX4, P-gp, and MRP1.
-
Neuropharmacology
Novel mechanism of hypidone hydrochloride (YL-0919) in Parkinson's disease: inhibiting neuronal ferroptosis by targeting the Sigma1R-PI3K-AKT-ACSL4 axis. [Abstract]2026 Jul 1:292:110950. PMID: 41887568
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Neuropharmacology. 2026 Jul 1:292:110950. [Abstract]
The expressions of p-PI3K, PI3K, p-AKT, AKT, and ACSL4 in the SN of mice brain were detected by Western blot.
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Neuropharmacology. 2026 Jul 1:292:110950. [Abstract]
SH-SY5Y and PC12 cells were treated with MPP+ (1 mM) in the presence of YL-0919 (10 μg/mL) for 24 h, and expressions of p-PI3K, PI3K, p-AKT, AKT, and ACSL4 were detected by Western blot.
-
J Inflamm Res
CCL20 Expression via AKT-ERK1/2-AP1 Pathway in Mycoplasma Pneumoniae Infection: Implications for EMT and Cell Migration. [Abstract]2025 Apr 28:18:5727-5739. PMID: 40322529
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 28:18:5727-5739. [Abstract]
THP-1 cells were infected with M. pneumoniae at MOIs of 0, 10, 50, or 100 for 1 h, and protein expression levels were assessed by Western blot.
-
Viruses
Quercetin Regulates Autophagy to Inhibit PRRSV Replication Through the PI3K/Akt/mTOR Signaling Pathway. [Abstract]2025 Dec 17;17(12):1637. PMID: 41472306
Phospho-AKT1(Ser473) Antibody (YA227) purchased from MedChemExpress. Usage Cited in: Viruses. 2025 Dec 17;17(12):1637. [Abstract]
Quercetin suppresses the PI3K/Akt/mTOR signaling pathway. MARC-145 cells were infected with PRRSV (MOI of 0.8) and treated with quercetin for 48 h.
Verification Images
-
Western blot analysis of extracts from A549(lane 2(20μg) , MCF-7(lane 3(20μg) and Jurkat(lane 4(20ug) using Phospho-AKT1(HY-P80276 Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
-
Immunocytochemistry analysis of Hela cells treated with or without 100nM Calyculin A for 30 minutes labeling Phospho-AKT1(Ser473) with Phospho-AKT1(Ser473) Antibody (HY-P80276)at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with Phospho-AKT1(Ser473) Antibody (HY-P80276) at 1/50 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4 ℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
-
Immunocytochemistry analysis of C6 cells treated with or without 100nM Calyculin A for 30 minutes labeling Phospho-AKT1(Ser473) with A Phospho-AKT1(Ser473) Antibody (HY-P80276) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with Phospho-AKT1(Ser473) Antibody (HY-P80276)at 1/100 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4 ℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
-
Immunohistochemical analysis of paraffin-embedded mouse lung tissue using Phospho-AKT1 Antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded mouse lung tissue using Phospho-AKT1 Antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
Background
-
Function
AKT1 (protein kinase Bα, PKBα) is a serine/threonine kinase that functions as a central effector of the PI3K/AKT/mTOR signaling pathway, regulating cellular growth, survival, metabolism, proliferation, and differentiation across multiple tissues and cell types[1][2][3]. Activation of AKT1 occurs downstream of PI3K through phosphoinositide-dependent kinase-1 (PDK1) -mediated phosphorylation, enabling downstream regulation of targets involved in protein synthesis, apoptosis control, and metabolic adaptation[4][5]. Mechanistically, AKT1 contributes to angiogenesis, physiological tissue growth, immune-cell function, and stress-response signaling, making it a critical node in both normal physiology and disease-associated signaling networks[2][4][5]. In disease models, dysregulated AKT signaling is strongly associated with cancer, metabolic disorders, cardiovascular pathology, and inflammatory conditions, and constitutive activation of AKT-dependent pathways promotes oncogenic progression and therapeutic resistance[2][6][7]. Compared with related isoforms, AKT1 exhibits distinct biological functions despite substantial structural homology with AKT2 and AKT3; genetic studies demonstrate that AKT1 deficiency primarily causes growth retardation, whereas AKT2 deficiency induces insulin resistance and diabetes, and AKT3 loss predominantly affects brain development[4][5]. Isoform-specific investigations further show that AKT1 and AKT2 can exert non-redundant or even opposing effects on migration, invasion, inflammation, and fibrogenesis depending on cellular context[2][6][8]. For experimental applications, increasing efforts focus on developing AKT1-selective inhibitors and isoform-selective cellular models, which provide valuable tools for dissecting AKT isoform-specific signaling and for evaluating targeted therapeutic strategies with improved selectivity profiles[6][7][9].
-
Subcellular Localization
Cytoplasm; Nucleus; Cell membrane; Mitochondrion intermembrane space
-
Expression
Tissue_specificity:This protein is expressed in prostate cancer, and its expression level gradually increases from normal to malignant (protein level) . It is expressed in all human cell types analyzed to date. The phosphorylated form of Tyr-176 is significantly increased in the progressive stages of breast cancer (i.e., from normal to hyperplastic (ADH) , ductal carcinoma in situ (DCIS) , invasive ductal carcinoma (IDC) , and lymph node metastasis (LNMM) stages) . -
Subunit
Interacts with BTBD10 (By similarity). Interacts with KCTD20 (By similarity). Interacts (via the C-terminus) with CCDC88A (via its C-terminus). Interacts with GRB10; the interaction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts (via the C-terminus) with THEM4 (via its C-terminus). Interacts with and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). Interacts with KIF14; the interaction is detected in the plasma membrane upon INS stimulation and promotes AKT1 phosphorylation (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts with SYAP1 (via phosphorylated form and BSD domain); this interaction is enhanced in a mTORC2-mediated manner in response to epidermal growth factor (EGF) stimulation and activates AKT1 (PubMed:23300339). Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing dephosphorylation and subsequent activation of Akt/AKT1 (PubMed:28147277). Interacts with TMEM175; leading to formation of the lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of the cGAS-STING pathway by mediating phosphorylation of CGAS during mitosis, leading to its inhibition (PubMed:26440888)
-
SwissProt ID
-
Synonyms
AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_HUMAN antibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-Akt antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody;
-
Research Field
Neuroscience
Documentation
-
Data Sheet (263 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Guerau-de-Arellano M, et al. Akt isoforms in the immune system. Front Immunol. 2022 Aug 23;13:990874. [Content Brief]
[2]. Reyes-Gordillo K, et al. Akt1 and Akt2 Isoforms Play Distinct Roles in Regulating the Development of Inflammation and Fibrosis Associated with Alcoholic Liver Disease. Cells. 2019 Oct 29;8(11):1337. [Content Brief]
[3]. O'Neill BT, et al. Akt1 in the cardiovascular system: friend or foe? J Clin Invest. 2005 Aug;115(8):2059-64. [Content Brief]
[4]. Tellai AD, et al. The complex post-transcriptional regulation of genes coding for methionine adenosyl transferase: New insights for liver cancer. Biochimie. 2025 Nov;238(Pt A):19-28. [Content Brief]
[5]. Quambusch L, et al. Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Nat Commun. 2021 Sep 6;12(1):5297. [Content Brief]